[Biomarkers in primary ovarian cancers and after chemotherapy].
The authors analyzed the expression of oncogen and antioncogen proteins using immunoperoxidase technique with monoclonal antibodies in 49 primary ovarian carcinomas and 38 cancers after chemotherapy (second look) There was not found independent prognostic marker. But some results suggest, that in the individual cases estimate proliferative activity and overexpression P53 may give some information about intensitivity and quality of chemotherapy.
Kedzia
W
W
I Katedry Ginekologii i Połoznictwa AM w Poznaniu.
Brazert
J
J
Kedzia
H
H
D000911:Antibodies, Monoclonal / Q000276:immunology; D015415:Biomarkers; D002277:Carcinoma / Q000235:genetics* / Q000276:immunology / Q000473:pathology / Q000532:radiotherapy*; D002478:Cells, Cultured; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D015870:Gene Expression / Q000235:genetics; D006801:Humans; D007124:Immunoenzyme Techniques; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000276:immunology / Q000473:pathology / Q000532:radiotherapy*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
D000911:Antibodies, Monoclonal; D015415:Biomarkers; D016159:Tumor Suppressor Protein p53